Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
Rylee Johns, PharmD Candidate
Advertisement
Articles by Rylee Johns, PharmD Candidate
Advertisement
Latest Updated Articles
Evolving Strategies for RSV Prevention in InfantsPublished: September 29th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Bacteria and Fungi in the Mouth Found to Drive Pancreatic Cancer Risk
2
Pfizer Agrees to Lower Certain Drug Prices in US, Aligning With ‘Most-Favored Nation’ Plan
3
Expert: Pharmacists Guide the Future of Gene Therapy in Oncology and Hematology
4
Op-Ed: Why Pharmacy Benefits Need a New Approach
5
